ArticleJCO oncology practice2023
Health Care Contact Days Experienced by Decedents With Advanced GI Cancer.
Article in JCO oncology practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Time toxicity in cancer care: a systematic review of definitions and measurement methods.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).JCO oncology practice · 2025Trial
- Characterizing the Objective Time Spent on Health Care Activities in Clinic and at Home for Patients With Cancer.Cancer medicine · 2026Article
- Healthcare contact days in cancer survivors relative to those with no cancer history.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Trajectories of health care contact days experienced by decedents who underwent curative-intent surgery for pancreatic cancer.The oncologist · 2026Article
- Accuracy of patient, care partner, and clinician health care contact day recall.The oncologist · 2026Article
- Article
- Safety and Efficacy of Concomitant Administration of Nanoliposomal Irinotecan + 5-Fluorouracil/Levo-Leucovorin for Pancreatic Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- Time toxicity associated with treatment of metastatic or unresectable gastro-oesophageal cancers in the second-line setting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- A novel patient-centered outcome in cancer care, days at home: a scoping review and guide for its future use.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Oncologist perspectives on the time toxicity of palliative systemic treatments for advanced cancer.JNCI cancer spectrum · 2026Article
- Time toxicity during palliative chemotherapy for advanced malignancies: a prospective study.BMJ supportive & palliative care · 2025Observational
- Characterizing and Addressing the Financial, Time, and Administrative Burdens of Cancer and its Care.Current treatment options in oncology · 2025Review
- Health Care Contact Days in Older Adults With Metastatic Cancer.JAMA network open · 2025Article
- Measuring the Unseen Burden: Immunotherapy and Targeted Therapy Reduce Treatment-Related Time Toxicity in Incurable Malignancies.World journal of oncology · 2025Article
- Patient-, care partner-, and clinician-proposed solutions to address the time toxicity of cancer care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Cost4Visit: a cross-sectional cohort study on hidden costs among surgical patients and relatives for in-person and video visits.BMJ open quality · 2025Article
- Comparing the time spent in clinic by patients receiving, subcutaneous and intravenous formulations of cancer drugs: A pilot study.Journal of cancer policy · 2025Article
- Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of life.The oncologist · 2025Article
- Health Care Contact Days and Outcomes in Clinical Trials vs Routine Care Among Patients With Non-Small Cell Lung Cancer.JAMA network open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeFrequent visits to health care facilities can be time intensive and all-consuming for people with cancer. We measured health care contact days (days with healthcare contact outside the home) among decedents with advanced GI cancer and examined sources of contact days, their associations with demographic and clinical factors, and their temporal patterns over the course of illness.
methodsWe conducted a retrospective cohort study using a tumor registry and electronic medical record data for decedents with stage IV GI cancer between 2011 and 2019 in a large health care network in MN. We determined contact days from diagnosis to death using chart review. Using multivariable beta regression adjusted for sociodemographic and clinical characteristics offset by survival, we calculated adjusted estimates of contact days and determined patient-level factors associated with percentage of contact days.
resultsWe identified 809 patients eligible for analysis (median [IQR] age at diagnosis, 65 [56-73] years). The median (IQR) overall survival was 175 (56-459) days. Patients spent a median (IQR) of 25.8% (17.4%-39.1%) of these as contact days. Of these days, 83.6% were spent on outpatient visits. In the multivariable analysis, older age, Black race, and never receiving systemic cancer-directed treatment were associated with a higher percentage of contact days. The percentage of contact days was highest in the first month after diagnosis (39.6%) and before death (32.2%), with a more moderate middle phase (U-shaped curve).
conclusionDecedents with advanced GI cancer spend 1 in 4 days alive with health care contact, despite a median survival of under 6 months. This is even higher immediately postdiagnosis and near death. These findings highlight the need to understand sources of variation, benchmark appropriate care, and deliver more efficient care for this vulnerable population with limited time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.